Parvus Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
South San Francisco, California, United States
Type:
sample
Technology:
sample
sample
About: Parvus Therapeutics Inc. is a privately held biopharmaceutical company developing Navacims™, a platform technology based on foundational research published in 2016 (Nature 530:434), to treat autoimmune diseases. Parvus’ mission is to shift the treatment paradigm toward Navacim-directed immune regulation, avoiding non-specific immune suppression associated with current therapies. Parvus’ innovative approach has the potential to benefit millions of patients suffering from debilitating autoimmune diseases and other chronic inflammatory conditions. Parvus is advancing a pipeline of proprietary drug candidates for multiple autoimmune indications through preclinical development and into the clinical. Parvus’ leadership team is experienced in successful drug discovery, development, manufacturing, regulatory approval, and commercialization.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Parvus Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.